[{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"MycoMedica Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ MycoMedica Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ MycoMedica Life Sciences"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Avance Clinical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Avance Clinical","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Avance Clinical"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"MindBio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ MindBio Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ MindBio Therapeutics"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Divestment","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EB-003","moa":"5-HT2A|5-HT1B","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"PureForm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Enveric Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Enveric Biosciences"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"MONGOLIA","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Enveric Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Enveric Biosciences"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Akos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"EV102","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"Enveric Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Akos Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Enveric Biosciences \/ Akos Biosciences"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EVM201","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EVM301","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EVM301","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"MONGOLIA","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Enveric Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Enveric Biosciences \/ Enveric Biosciences"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Diverse Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Enveric Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Enveric Biosciences \/ Enveric Biosciences"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Restoration Biologics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Enveric Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Restoration Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Enveric Biosciences \/ Restoration Biologics"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"EB-003","moa":"5-HT2A|5-HT1B","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"EB-003","moa":"5-HT2A|5-HT1B","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EB-003","moa":"5-HT2A|5-HT1B","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Enveric Biosciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : The net proceeds from the offering for product development, including EB-003, the first known compound designed to selectively engage both 5-HT₂A and 5-HT₁B receptors.

                          Product Name : EB-003

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          September 18, 2025

                          Lead Product(s) : EB-003

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $2.2 million

                          Deal Type : Private Placement

                          blank

                          02

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : The net proceeds from the offering for product development, including EB-003, the first known compound designed to selectively engage both 5-HT₂A and 5-HT₁B receptors.

                          Product Name : EB-003

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          September 17, 2025

                          Lead Product(s) : EB-003

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $2.2 million

                          Deal Type : Private Placement

                          blank

                          03

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : EB-003 is a novel neuroplastogen that engages both the 5-HT2A and 5-HT1B receptors, a dual mechanism that may define a new class of neuropsychiatric treatments.

                          Product Name : EB-003

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 16, 2025

                          Lead Product(s) : EB-003

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : EB-003 is a first-in-class, neuroplastogen designed to selectively engage serotonin 5-HT2A and 5-HT1B receptors, being investigated for PTSD.

                          Product Name : EB-003

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 28, 2025

                          Lead Product(s) : EB-003

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : EB-003 is the lead compound from Enveric’s proprietary EVM301 Series, which stimulates synaptic plasticity without incurring hallucinogenic liability in patients with depression.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 28, 2025

                          Lead Product(s) : EB-003

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Under the licensing agreement, Restoration will gain the rights of cannabinoid-COX-2 conjugate compounds. It is being used for the joint pathology, such as osteoarthritis and rheumatoid arthritis.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 04, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Undisclosed

                          Sponsor : Restoration Biologics

                          Deal Size : $61.0 million

                          Deal Type : Licensing Agreement

                          blank

                          07

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : The net proceeds from the offering will be used to fund the clinical development of EB-003 for the treatment of reatment of difficult-to-address anxiety, depression and other disorders.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          February 03, 2025

                          Lead Product(s) : EB-003

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $5.0 million

                          Deal Type : Public Offering

                          blank

                          08

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : EB-003, is a first-in-class neuroplastogen designed to eliminate hallucinations in patients with anxiety, depression.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 25, 2024

                          Lead Product(s) : EB-003

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : MycoMedica will seek to develop EB-002, formerly EB-373, a synthetic prodrug of the active metabolite psilocin, in treatment of neuropsychiatric disorders such as depression.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          November 12, 2024

                          Lead Product(s) : Psilocybin Prodrug

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : MycoMedica Life Sciences

                          Deal Size : $62.0 million

                          Deal Type : Licensing Agreement

                          blank

                          10

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : EB-003, is a first-in-class neuroplastogen designed to eliminate hallucinations in patients with anxiety, depression.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 15, 2024

                          Lead Product(s) : EB-003

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank